

# The Novartis Commitment to Patients and Caregivers

Only by working together and delivering on the four pillars of our Commitment, can we improve outcomes for patients and change the practice of medicine

40+

**PATIENT ORGANIZATIONS** representing

200m

**PATIENTS** contributed to its development

110 000

**NOVARTIS ASSOCIATES**<sup>1</sup> own it as an aspiration to embed the perspective of patients and caregivers systematically in our decision-making

## Our Commitment is based on four pillars



Respecting and understanding the patient community perspective



Conducting responsible clinical trials



Expanding access to our medicines



Recognizing the importance of transparency and reporting

## Sharing three years of progress

67%

### EARLY RESEARCH PROGRAMS

in general medicines obtained patient insights before first in human trials (healthy volunteers). Piloted patient panels for five Proof of Concept indications

9 998

### PATIENTS REACHED THROUGH MANAGED ACCESS PROGRAMS<sup>4</sup>

94% of requests approved for 64 compounds in 82 countries - providing pre-approval access to Novartis medicines; More than 14 000 patients are currently on treatment via MAPs\*

44

### CLINICAL DEVELOPMENT PROGRAMS<sup>2</sup>

comprising 69 clinical trials, had a patient engagement component to obtain the patient perspective on the design and/or conduct of clinical trials

90

### CLINICAL TRIALS

included Patient Reported Outcomes (PRO) conducted in 57 countries

95

### SIMPLIFIED SUMMARIES<sup>3</sup>

from Phase 1 - 4 clinical trials sent to investigators to share with 14 668 trial participants and posted on [novartisclinicaltrials.com](http://novartisclinicaltrials.com)

66m

### PATIENTS<sup>5</sup>

reached through access approaches

<sup>1</sup> 2020 data

<sup>2</sup> Patient engagement component defined as interaction with patients to seek input, advice or guidance

<sup>3</sup> [www.novctrd.com/#/terms](http://www.novctrd.com/#/terms)

<sup>4</sup> [www.novartis.com/our-focus/healthcare-professionals/managed-access-programs](http://www.novartis.com/our-focus/healthcare-professionals/managed-access-programs)

<sup>5</sup> [www.novartis.com/investors/novartis-annual-reporting-suite](http://www.novartis.com/investors/novartis-annual-reporting-suite)

\* See also COVID related information on page 2

# Our Commitment to Patients and Caregivers

## 2020 facts and figures



### Respecting and understanding the patient community perspective

Connecting over 700 patient advocates in over 40 countries across Europe, US and MEA with digitally enabled technology, with the European Patient Innovation Summit (EPIS)

119 patient organizations in 35 disease areas from 35 countries engaged in global initiatives to inform decision-making<sup>1</sup>

22 capability and capacity building programs of patient organizations supported<sup>1</sup>

19 co-created initiatives between patient organizations and Novartis for disease education, awareness and research collaborations<sup>1</sup>

#4 ranking in Corporate Reputation – evaluated by over 1 800 patient organizations<sup>2</sup>

#1 reputation ranking in Psoriasis<sup>2</sup>

#2 reputation ranking in Cancer, Autoimmune disease, Neurological disorders<sup>2</sup>



### Expanding access to our medicines<sup>4</sup>

#2 in Access to Medicines Index – assessing companies' performance in providing access to medicines for patients

369 000 patients reached in 50+ lower income countries with 118 emerging market brands

4.5 million patients reached through Novartis Access since launch of the program offering a portfolio of on- and off-patent medicines addressing key non-communicable diseases and childhood pneumonia in lower-income countries

8 million people reached with health education and awareness events



### Conducting responsible clinical trials

During the COVID-19 pandemic, 3 device trials were switched from “in-hospital administration” to “patient self-administration at home”, to reduce the burden of treatment and avoid trial disruption

7 trials are piloting remote trial participation with home nursing services

Trial feedback questionnaires from 30 clinical trials sent to patients to obtain insights on their participation experience; 2 500 patient responses were received from 40 countries

179 clinical trials listed for secure, voluntary data sharing on ClinicalStudyDataRequest.com CSDR<sup>3</sup>

10 clinical trials set up to pilot return of individual results to trial participants (IRR) once the clinical trial report is publicly available

10 clinical trials used novel digital measures, utilizing patient-worn sensors and applications, to gain better insights into patient function and patient performance

\*About 4 500 patients with COVID-19 related conditions received medicines in response to unsolicited Managed Access requests from healthcare institutions and governments



### Recognizing the importance of transparency and reporting

2 799 clinical trials posted on [novartisclinicaltrials.com](http://novartisclinicaltrials.com), sharing results of clinical trials with society

Returning to society with 11 manuscripts and 26 posters/abstracts published on insights obtained from the patient community, to share the learnings

Reported engagement with and support for 1 481 patient organizations in 69 countries in Transfer of Value report<sup>5</sup>

<sup>1</sup> Refers to global and regional initiatives/activities only

<sup>2</sup> The Corporate Reputation of Pharma in 2019, published April 2020

<sup>3</sup> [www.clinicalstudydatarequest.com/](http://www.clinicalstudydatarequest.com/)

<sup>4</sup> [www.novartis.com/sites/www.novartis.com/files/novartis-in-society-report-2019.pdf](http://www.novartis.com/sites/www.novartis.com/files/novartis-in-society-report-2019.pdf)

<sup>5</sup> [www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/patient-group-funding](http://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/patient-group-funding)

\* Numbers in addition to overall MAP access on page 1